© 2020 MJH Life Sciences and Cure Today. All rights reserved.
© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.
August 18th 2020, 9:24pm
While the use of CAR-T cell therapy is currently still being investigated in patients with multiple myeloma, Dr. Nina Shah of the UCSF Helen Diller Family Comprehensive Cancer Center believes that these clinical trials will be what ultimately moves the field forward.
August 18th 2020, 6:15pm
The future of multiple myeloma is heading toward combination therapies and CAR-T cell treatments, according to Dr. Betsy O'Donnell.
August 17th 2020, 6:00pm
On social media, CURE® recently asked its readers to share how they pamper and treat themselves during or after their cancer treatment. Here, we share some of their responses.
August 6th 2020, 5:56am
The Food and Drug Administration approved Blenrep to treat patients with relapsed/refractory multiple myeloma.
August 4th 2020, 1:00am
On social media, CURE® recently asked its readers to share the advice they would give someone looking to help a friend or loved one with cancer. Here, we share some of their responses.
July 31st 2020, 10:03pm
Dr. Parameswaran Hari discusses the importance of understanding a patient’s MRD if they are receiving the maintenance therapy Sarclisa for multiple myeloma.
July 29th 2020, 10:00pm
The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.
July 24th 2020, 5:00pm
Patients with multiple myeloma who were obese or overweight had a trend toward slightly improved progression-free survival and overall survival outcomes compared to patients who had a normal weight, according to data from an exploratory analysis.
July 21st 2020, 1:00am
A roundup of the latest news and updates for patients with multiple myeloma from CURE®.
July 15th 2020, 10:00pm
The manufacturer is working with the Food and Drug Administration to address any requests including changes to the protocol of the MELANI-01 trial to enhance patient safety.